Hubbry Logo
search button
Sign in
Anistreplase
Anistreplase
Comunity Hub
MainMain
History
arrow-down
starMore
arrow-down
Sign in
Sign in
bob

Bob

Have a question related to this hub?

bob

Alice

Got something to say related to this hub?
Share it here.

#general is a chat channel to discuss anything related to the hub.
Hubbry Logo
search button
Sign in
Anistreplase
Anistreplase
Community hub for the Wikipedia article
logoWikipedian hub
Anistreplase
Anistreplase
Main
Welcome to the community hub built on top of the Anistreplase Wikipedia article. Here, you can discuss, collect, and organize anything related to Anistreplase. The purpose of the hub is to connect people,...
Add your contribution
Media Collections
0
Timelines
0
Articles
0
Notes collections
0
Days in Chronicle
0
Anistreplase
Anistreplase
Clinical data
Trade namesEminase
AHFS/Drugs.comMicromedex Detailed Consumer Information
ATC code
Pharmacokinetic data
Elimination half-life90 minutes
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Molar massapprox. 131 kg/mol
  (verify)

Anistreplase is a thrombolytic drug. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC). As a thrombolytic drug, it is used to treat blood clots in emergency situations.

Uses

[edit]

Anistreplase is used to treat blood clots in emergency situations such as myocardial infarction.[1] Early treatment gives better outcomes.[1]

History

[edit]

Anistreplase has been developed by Beecham under the brand name Eminase. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC) after its components.[1][2][3]

References

[edit]
  1. ^ a b c Rawles J (27 January 1996). "Magnitude of benefit from earlier thrombolytic treatment in acute myocardial infarction: new evidence from Grampian region early anistreplase trial (GREAT)". British Medical Journal. 312 (7025): 212–5. doi:10.1136/bmj.312.7025.212. PMC 2350007. PMID 8563585.
  2. ^ Hannaford P, Vincent R, Ferry S, Hirsch S, Kay C (April 1995). "Assessment of the practicality and safety of thrombolysis with anistreplase given by general practitioners". Br J Gen Pract. 45 (393): 175–9. PMC 1239197. PMID 7612317.
  3. ^ Rawles J, Light J (October 1993). "Loss of quality adjusted days as a trial endpoint: effect of early thrombolytic treatment in suspected myocardial infarction. Grampion Region Early Anistreplase Trial (GREAT)". J Epidemiol Community Health. 47 (5): 377–381. doi:10.1136/jech.47.5.377. PMC 1059832. PMID 8289038.
Stub icon

This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.

Hub tags